Expert Review of Cardiovascular Therapy最新文献_第7页

Association between pre-existing heart failure and in-hospital outcomes and management in admissions with cardiogenic shock. 心源性休克入院时既往心力衰竭与住院结局及处理的关系

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-29 DOI: 10.1080/14779072.2026.2650527

Carlos Diaz-Arocutipa, Rafael Salguero-Bodes, Roberto Martín-Asenjo, Lourdes Vicent

{"title":"Association between pre-existing heart failure and in-hospital outcomes and management in admissions with cardiogenic shock.","authors":"Carlos Diaz-Arocutipa, Rafael Salguero-Bodes, Roberto Martín-Asenjo, Lourdes Vicent","doi":"10.1080/14779072.2026.2650527","DOIUrl":"10.1080/14779072.2026.2650527","url":null,"abstract":"Background: Cardiogenic shock (CS) remains highly lethal despite advances in care. Preexisting heart failure (HF) is common in CS, but its effect on outcomes and management is unclear.Research design and methods: Using the 2016-2019 National Inpatient Sample, we identified adults (≥18 years) hospitalized with CS and categorized them by presence of preexisting HF. The primary outcome was in-hospital mortality; secondary outcomes included pulmonary artery catheterization, mechanical circulatory support (MCS), renal replacement therapy, major bleeding, length of stay, and hospital charges. Multivariable logistic regression adjusted for demographics, comorbidities, and hospital characteristics.Results: Of 640,660 CS admissions, 65.4% had HF. They were older, had more comorbidities, and were more often treated in large urban teaching hospitals. HF was associated with lower in-hospital mortality (adjusted odds ratio [aOR] 0.58; 95% CI 0.56-0.60; p < 0.001), but greater use of pulmonary artery catheterization (aOR 1.76), MCS (aOR 1.33), and renal replacement therapy (aOR 1.11). HF patients had longer stays (+1.6 days), higher charges (+$23,197), and less major bleeding (aOR 0.74; p < 0.001).Conclusions: Preexisting HF is associated with a distinct CS phenotype, including lower in-hospital mortality and higher resource utilization, highlighting the need for phenotype-specific strategies and refined risk models in CS management.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"385-392"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimal treatment choices for adult atrial septal defects: the role of appropriate risk stratification. 成人房间隔缺损的最佳治疗选择：适当风险分层的作用。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-02 DOI: 10.1080/14779072.2026.2653712

Umit Yasar Sinan, Neziha Aybuke Geylan, Arzu Bakimci Simsek, Mehmet Serdar Kucukoglu

{"title":"Optimal treatment choices for adult atrial septal defects: the role of appropriate risk stratification.","authors":"Umit Yasar Sinan, Neziha Aybuke Geylan, Arzu Bakimci Simsek, Mehmet Serdar Kucukoglu","doi":"10.1080/14779072.2026.2653712","DOIUrl":"10.1080/14779072.2026.2653712","url":null,"abstract":"Introduction: Adult atrial septal defect (ASD) is no longer regarded as a benign congenital lesion, as long-term follow-up studies have demonstrated substantial risks of atrial arrhythmias, heart failure (HF), pulmonary hypertension (PH), and excess mortality. Optimal treatment selection in adults therefore requires risk stratification beyond defect size and shunt magnitude alone. Importantly, adult ASD management increasingly demands a physiology-driven and patient-centered approach rather than a purely anatomical paradigm.Areas covered: This narrative expert review summarizes contemporary evidence on treatment strategies for adult ASD, focusing on surgical and transcatheter closure and the role of individualized risk stratification. A structured literature search was performed using PubMed and Embase databases, covering studies published up to 2024, including observational cohorts, registry data, and guideline documents addressing long-term outcomes, timing of intervention, and predictors of adverse events in adult ASD populations.Expert opinion: Risk-based decision-making should be central to adult ASD management, integrating age, atrial arrhythmia burden, right ventricular (RV) remodeling, pulmonary vascular disease, and comorbidities This review translates existing evidence into a practical decision-oriented framework. Future strategies should move away from a 'one-size-fits-all' closure approach toward personalized treatment pathways within specialized adult congenital heart disease (ACHD) programs.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"301-307"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in the management of cardiac sarcoidosis. 人工智能在心脏结节病治疗中的应用。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-05-08 DOI: 10.1080/14779072.2026.2669537

Claudio Tana, Nicol Bernardinello, Paolo Spagnolo, Livia Moffa

引用次数: 0

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-27 DOI: 10.1080/14779072.2026.2649153

Laura Acar, Christian-Alexander Behrendt, Ursula Marschall, Martial Mboulla Nzomo, Evaldas Girdauskas

{"title":"Sex-related differences in the prognosis of asymptomatic mitral regurgitation: an analysis of nationwide claims data.","authors":"Laura Acar, Christian-Alexander Behrendt, Ursula Marschall, Martial Mboulla Nzomo, Evaldas Girdauskas","doi":"10.1080/14779072.2026.2649153","DOIUrl":"10.1080/14779072.2026.2649153","url":null,"abstract":"Background: Asymptomatic mitral regurgitation (MR) can lead to long-term morbidity and mortality. While sex differences are well established in cardiovascular disease, data for asymptomatic MR are limited. Systemic factors such as cancer may affect prognosis through shared pathways.Research design and methods: We conducted a cohort study using German claims data from the BARMER health insurance, identifying asymptomatic MR by repeated outpatient diagnoses without baseline complications or interventions, matched 1:1 by age and sex to controls without cardiovascular disease. Outcomes included 10-year MR-related complications, mitral valve interventions, incident cancer, and all-cause mortality. Multivariable Cox models adjusted for age, comorbidity (Elixhauser index), and cancer status.Results: Among 56.577 asymptomatic MR patients (67% female, median age 68), males had higher MR-related complication rates (51.5% vs 44.0%) and lower 10-year survival (73.8% vs 81.8%, both p < 0.001). Cancer increased mortality risk (adjusted hazard ratios [aHR] 1.88, 95% CI 1.79-1.98), while male sex remained an independent predictor for mortality (aHR 1.42, 95% CI 1.36-1.47).Conclusions: Asymptomatic MR follows a progressive clinical trajectory, with high complication rates despite low intervention rates. Within this trajectory, males showed a significant survival disadvantage after adjusting for comorbidity and cancer, supporting risk-based and sex-aware follow-up strategies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"375-384"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoids and outcome improvement in heart failure patients with and without atrial fibrillation: a systematic review and a meta-analysis. 矿化皮质激素对伴有和不伴有心房颤动的心力衰竭患者预后的改善：一项系统综述和荟萃分析。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-29 DOI: 10.1080/14779072.2026.2650525

Bernadette Corica, Elisa Battigaglia, Giulio Francesco Romiti, Jacopo Francesco Imberti, Davide Antonio Mei, Niccolò Bonini, Marco Vitolo, Giuseppe Boriani

{"title":"Mineralocorticoids and outcome improvement in heart failure patients with and without atrial fibrillation: a systematic review and a meta-analysis.","authors":"Bernadette Corica, Elisa Battigaglia, Giulio Francesco Romiti, Jacopo Francesco Imberti, Davide Antonio Mei, Niccolò Bonini, Marco Vitolo, Giuseppe Boriani","doi":"10.1080/14779072.2026.2650525","DOIUrl":"10.1080/14779072.2026.2650525","url":null,"abstract":"Background: The presence of atrial fibrillation (AF) in patients with heart failure (HF) is common and increases the risk of adverse events. Whether the benefit of mineralocorticoid receptor antagonists (MRAs) in patients with HF varies according to AF remains to be understood.Research design and methods: We systematically searched MEDLINE and EMBASE and included all studies reporting prevalence of AF and incidence of a composite primary outcome of cardiovascular death and HF hospitalization. Random-effects models were used to estimate pooled odds ratios (OR), 95% confidence intervals (CI), and prediction intervals (PI).Results: Two thousand five hundred and eighty-two articles were screened, and five studies were included. Prevalence of AF in HF patients was 34.5% (95% CI: 24.8-45.8%; 95% PI: 9.4-72.8%). MRAs appeared similarly effective in reducing the risk of the primary outcome among HF patients with AF (OR: 0.91; 95% CI: 0.63-1.31) and without AF patients (OR: 0.80; 95% CI: 0.71-0.90) (subgroup difference p = 0.495). Meta-regression identified female sex, hypertension, prior HF hospitalization, and beta-blocker use as potential moderators of the risk of the primary outcome in patients with HF and AF.Conclusions: One-third of HF patients included in RCT trials on MRAs have AF. MRAs improved outcomes with an effect that results not different in HF patients with and without AF.Registration: The PROSPERO identification number is CRD420251007396.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"365-373"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond successful atrial fibrillation ablation: unmet patient needs, quality-of-life gap and patients' perspective. 成功的房颤消融之外：未满足的患者需求，生活质量差距和患者的观点。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-03-25 DOI: 10.1080/14779072.2026.2649159

Andrea Matteucci, Marco Valerio Mariani, Luca Sgarra, Michela Bonanni, Nicola Pierucci, Vincenzo Mirco La Fazia, Silvio Fedele, Federico Nardi, Furio Colivicchi

引用次数: 0

Management patterns of acute coronary syndrome among patients with malignancy: a systematic review and meta-analysis. 恶性肿瘤患者急性冠状动脉综合征的管理模式：系统回顾和荟萃分析。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-04-01 Epub Date: 2026-04-27 DOI: 10.1080/14779072.2026.2661849

Muhammad Ahmad Nadeem, Abdullah Ahmad, Abdul Rafeh Awan, Rudra Pratap Singh, Nicole Collantes Silva, Syed Hasham Ali, Meher Ayyazuddin, Bakhtawar Haseeb, Muhammad Daniyal, Baryalay Khan, Amir Humza Sohail, Abu Baker Sheikh

{"title":"Management patterns of acute coronary syndrome among patients with malignancy: a systematic review and meta-analysis.","authors":"Muhammad Ahmad Nadeem, Abdullah Ahmad, Abdul Rafeh Awan, Rudra Pratap Singh, Nicole Collantes Silva, Syed Hasham Ali, Meher Ayyazuddin, Bakhtawar Haseeb, Muhammad Daniyal, Baryalay Khan, Amir Humza Sohail, Abu Baker Sheikh","doi":"10.1080/14779072.2026.2661849","DOIUrl":"10.1080/14779072.2026.2661849","url":null,"abstract":"Introduction: Patients presenting with acute coronary syndrome (ACS) and a history of cancer are high-risk. Prior studies suggest differences in acute treatment and discharge prescribing compared with non-cancer patients.Methods: PubMed, Scopus, Embase, andClinicalTrials.gov were searched on 24 January 2025, for studies published between 2000 and 2025. Studies comparing ACS management and medication use in patients with versus without a history of malignancy were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.Results: Seventeen studies were included. During hospitalization, cancer patients with ACS were significantly less likely to undergo percutaneous coronary intervention (PCI), receive drugeluting stents, or receive glycoprotein IIb/IIIa inhibitors (all p < 0.001), compared to non-cancer patients. No significant differences were observed in the administration of beta-blockers (p = 0.26) or P2Y12 inhibitors (p = 0.39). At discharge, cancer patients were less likely to be prescribed dual antiplatelettherapy (p = 0.02), aspirin (p < 0.001), beta-blockers (p = 0.03), and statins (p = 0.02). No significant differences were found in prescriptions for P2Y12 inhibitors, oral anticoagulants, nitrates, calcium channel blockers, or ACE inhibitors/ARBs.Conclusions: Differences in treatment persist in both in-hospital management and discharge prescribing for cancer patients with ACS, underscoring the need for standardized, evidence-based protocols to ensure equitable care.Registration: This meta-analysis was prospectively registered with PROSPERO (CRD420251275640.).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"463-474"},"PeriodicalIF":2.1,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prioritizing surgical ablation for atrial fibrillation during coronary artery bypass grafting: new evidence, old debate. 冠状动脉旁路移植术中房颤优先手术消融：新证据，旧争论。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-01-01 Epub Date: 2025-12-18 DOI: 10.1080/14779072.2025.2603981

Ely Erez, John J Squiers, Cody W Dorton, Jasjit Banwait, Alessandro Gasparini, Michael Mack, J Michael DiMaio, Justin M Schaffer

{"title":"Prioritizing surgical ablation for atrial fibrillation during coronary artery bypass grafting: new evidence, old debate.","authors":"Ely Erez, John J Squiers, Cody W Dorton, Jasjit Banwait, Alessandro Gasparini, Michael Mack, J Michael DiMaio, Justin M Schaffer","doi":"10.1080/14779072.2025.2603981","DOIUrl":"10.1080/14779072.2025.2603981","url":null,"abstract":"Introduction: Atrial fibrillation (AF) affects 10-20% of patients undergoing coronary artery bypass grafting (CABG) and is associated with increased postoperative morbidity and mortality. Although studies support the safety and effectiveness of surgical ablation (SA), and guidelines recommend its use during CABG for patients with preexisting AF, clinical adoption remains limited.Areas covered: In this review, we outline current guideline recommendations, evaluate the evidence base, highlight recent analyses, and examine persistent barriers to the adoption of SA during CABG, informed by studies identified through searches of PubMed and Google Scholar.Expert opinion: Small randomized studies demonstrate that SA restores sinus rhythm following CABG, while observational studies suggest rhythm restoration improves survival and reduces thromboembolic events. Recent national database analyses have lent further support, finding an association between SA and long-term survival. Analytic approaches included analysis by treatment type using propensity-score risk adjustment and, more recently, using surgeon frequency of SA as an instrumental variable. However, concerns about unmeasured confounding, sparse rhythm follow-up, and limited lesion-set granularity undermine confidence and contribute to underuse. A randomized trial comparing long-term outcomes between pulmonary vein isolation, left atrial, and bi-atrial lesion sets is critically needed to guide optimal implementation of SA during CABG.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"5-13"},"PeriodicalIF":2.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of mineralocorticoid receptor antagonists on cardiometabolic profile and liver health in individuals with increased cardiometabolic risk: a systematic review and meta-analysis of randomized controlled trials. 矿皮质激素受体拮抗剂对心脏代谢风险增加个体的心脏代谢特征和肝脏健康的影响：随机对照试验的系统回顾和荟萃分析

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-01-01 Epub Date: 2026-02-26 DOI: 10.1080/14779072.2026.2634029

João Dias, Ana Rita Leite, Tiago Godinho, Joana Correia-Chaves, Marta Borges-Canha, Adelino Leite-Moreira, João Sérgio Neves

{"title":"Effects of mineralocorticoid receptor antagonists on cardiometabolic profile and liver health in individuals with increased cardiometabolic risk: a systematic review and meta-analysis of randomized controlled trials.","authors":"João Dias, Ana Rita Leite, Tiago Godinho, Joana Correia-Chaves, Marta Borges-Canha, Adelino Leite-Moreira, João Sérgio Neves","doi":"10.1080/14779072.2026.2634029","DOIUrl":"10.1080/14779072.2026.2634029","url":null,"abstract":"Introduction: Recent studies link overactivation of mineralocorticoid receptors to insulin resistance, inflammation, and metabolic dysfunction-associated steatotic liver disease. We aimed to assess the effects of mineralocorticoid receptor antagonists (MRAs) on liver steatosis, fibrosis, inflammation, and cardiometabolic risk.Methods: We conducted a systematic review and meta-analysis including placebo-controlled randomized controlled trials (RCTs) assessing MRAs' effects. A random-effects meta-analysis assessed MRAs effects on anthropometry, lipid profile, inflammatory parameters, and glucose metabolism. Outcomes were presented as mean differences (MD) with 95% confidence intervals (95% CI). Twenty-six studies were included and seventeen were meta-analyzed. MRAs studied included spironolactone, eplerenone, canrenone, apararenone, and finerenone. Most studies included participants with diabetes, metabolic syndrome, obesity, heart failure, or hypertension.Results: In the meta-analysis, we found a mild but significant decrease in body weight (MD = -1.27, 95% CI [-2.54, -0.01]) and a trend for higher HbA1c (MD = 0.13, 95% CI [-0.01, 0.27]) with MRAs. There was a trend toward a decrease in C-reactive protein levels (MD = -0.99, 95% CI [-2.22, 0.24]) with MRAs. RCTs on liver function and structure showed no differences compared to placebo.Conclusions: MRAs appear to have a mild impact on metabolic and inflammatory parameters in patients with increased cardiometabolic risk. However, more RCTs on MRAs' cardiometabolic impact are needed.Registration: This study was registered with PROSPERO (CRD42025632202).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"235-252"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical approaches for determining idiopathic and inflammatory dilated cardiomyopathy in women. 确定女性特发性和炎性扩张型心肌病的临床方法。

IF 2.1

Expert Review of Cardiovascular Therapy Pub Date : 2026-01-01 Epub Date: 2026-02-26 DOI: 10.1080/14779072.2026.2637752

Andrea Silvio Giordani, Caterina Menghi, Matteo Castegnaro, Anna Baritussio, Alida Linda Patrizia Caforio

引用次数: 0